6978 — Immunotech Biopharm Cashflow Statement
0.000.00%
Last trade - 00:00- HK$487.83m
- HK$813.06m
Annual cashflow statement for Immunotech Biopharm, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -355 | -321 | -335 | -186 | -231 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 59.9 | 51 | 106 | -22 | 66.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 19.1 | 45.1 | 12.3 | 21.8 | 12.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -255 | -181 | -164 | -126 | -97.3 |
| Capital Expenditures | -181 | -96.6 | -22.5 | -28.1 | -14.6 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -147 | 120 | -94.1 | 169 | -83.4 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -328 | 23.4 | -117 | 141 | -98.1 |
| Financing Cash Flow Items | -3.68 | -19.6 | -8.52 | -7.49 | -11.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -11 | -36.1 | 274 | -20.6 | 203 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -594 | -193 | -6.29 | -5.2 | 7.5 |